Anders Andersson1, Mattias Lindberg1,
Fu-Hua Wang1, Tomas Klason1
1AstraZeneca R&D,
Ketamine, given at subanesthetic doses, have been used in the literature to produce schizophrenic-like symptoms both in animals and man. In this study, phMRI was used to investigate the effects of a selective mGlur2/3 agonist (LY404039) on the Ketamine activation pattern. A SpinEcho EPI single shot sequence with USPIO contrast agent (Resovist) at 9.4T was used. The response was calculated as area-under-the-curve in defined brain regions, giving a significantly attenuated response from the LY404039 pretreated group compared with the saline control group. This shows a great potential of phMRI in drug research using the Ketamine induced schizophrenia model.